| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PNAS..113E1555T |
| P356 | DOI | 10.1073/PNAS.1521812113 |
| P8608 | Fatcat ID | release_ha6i3imwwjbolojse6vlrhmsw4 |
| P932 | PMC publication ID | 4801290 |
| P698 | PubMed publication ID | 26929325 |
| P5875 | ResearchGate publication ID | 296468311 |
| P50 | author | Ayumu Taguchi | Q47331721 |
| Satyendra C. Tripathi | Q50926692 | ||
| Mohit Kumar Jolly | Q61163134 | ||
| P2093 | author name string | Hui Liu | |
| Hong Wang | |||
| Haley L Peters | |||
| Herbert Levine | |||
| Eshel Ben-Jacob | |||
| Carmen Behrens | |||
| Ignacio I Wistuba | |||
| Samir M Hanash | |||
| Jeffrey J Molldrem | |||
| Jaime Rodriguez-Canales | |||
| Amin Momin | |||
| Hiroyuki Katayama | |||
| Edwin J Ostrin | |||
| Muge Celiktas | |||
| P2860 | cites work | The complexity of recognition of ubiquitinated substrates by the 26S proteasome | Q38122985 |
| STAT1 and STAT3 in tumorigenesis: A matter of balance. | Q38140881 | ||
| Tumor plasticity interferes with anti-tumor immunity | Q38221171 | ||
| STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes | Q38311269 | ||
| JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells | Q39020685 | ||
| S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma. | Q39113324 | ||
| Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. | Q39189278 | ||
| HLArestrictor--a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides | Q39631406 | ||
| Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells | Q40048868 | ||
| Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation | Q40333800 | ||
| Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1. | Q40597193 | ||
| Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes. | Q41887350 | ||
| Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells | Q47834590 | ||
| The turnover kinetics of major histocompatibility complex peptides of human cancer cells. | Q53650261 | ||
| IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer | Q63916123 | ||
| Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia | Q74268543 | ||
| Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells | Q77996264 | ||
| Cancer immunology | Q83365566 | ||
| Selective expression of S100A11 in lung cancer and its role in regulating proliferation of adenocarcinomas cells | Q84809412 | ||
| Cancer immunotherapy: moving beyond current vaccines | Q24548229 | ||
| A gene atlas of the mouse and human protein-encoding transcriptomes | Q24568043 | ||
| MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination | Q24598602 | ||
| Lung cancer signatures in plasma based on proteome profiling of mouse tumor models | Q24628852 | ||
| Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis | Q26799987 | ||
| Immune cell promotion of metastasis | Q26991724 | ||
| Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer | Q28393146 | ||
| TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence | Q28477306 | ||
| Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes | Q32142930 | ||
| Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. | Q34103901 | ||
| Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. | Q34122227 | ||
| Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation | Q34122245 | ||
| Tumor stress-induced phosphoprotein1 (STIP1) as a prognostic biomarker in ovarian cancer | Q34611741 | ||
| Identification of proteomic signatures associated with lung cancer and COPD. | Q34715428 | ||
| Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. | Q34880376 | ||
| The two faces of interferon-γ in cancer | Q35269015 | ||
| N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells | Q35380919 | ||
| A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets | Q35429274 | ||
| STAT proteins: From normal control of cellular events to tumorigenesis | Q35540165 | ||
| Regulation of immunoproteasome function in the lung | Q35623348 | ||
| Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes | Q35683291 | ||
| HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors | Q36025680 | ||
| A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice | Q36075303 | ||
| Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance | Q36092560 | ||
| Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. | Q36093867 | ||
| Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. | Q36839423 | ||
| Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors | Q37187543 | ||
| Clinical Use of Interferon-gamma | Q37675044 | ||
| Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme | Q37980553 | ||
| Emerging roles of immunoproteasomes beyond MHC class I antigen processing | Q37989860 | ||
| The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression | Q38010997 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| phenotype | Q104053 | ||
| immunoproteasome | Q106087471 | ||
| P304 | page(s) | E1555-64 | |
| P577 | publication date | 2016-02-29 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome | |
| P478 | volume | 113 |
| Q47098614 | A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer |
| Q58695217 | Activation of viral defense signaling in cancer |
| Q92422527 | Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression |
| Q90150435 | Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer |
| Q55691533 | Analysis of Hierarchical Organization in Gene Expression Networks Reveals Underlying Principles of Collective Tumor Cell Dissemination and Metastatic Aggressiveness of Inflammatory Breast Cancer. |
| Q38818628 | Antigen processing and immune regulation in the response to tumours |
| Q91820016 | Avelumab in non-small-cell lung cancer |
| Q91404355 | Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance |
| Q59798144 | Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC |
| Q91714177 | Comparative Study of Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal Spectrum |
| Q61811117 | Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment |
| Q52606685 | Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. |
| Q38616552 | Deciphering Epithelial-Mesenchymal Transition Regulatory Networks in Cancer through Computational Approaches |
| Q90312259 | Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression |
| Q38838108 | Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases. |
| Q39395614 | Epithelial-mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease. |
| Q33869760 | Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding? |
| Q60907747 | Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity |
| Q41428789 | Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy |
| Q89722643 | Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma |
| Q37121401 | Immunoproteasomes and immunotherapy-a smoking gun for lung cancer? |
| Q33767606 | Inflammatory breast cancer: a model for investigating cluster-based dissemination. |
| Q91869765 | Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer |
| Q49501422 | Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. |
| Q42336210 | Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017. |
| Q48647682 | Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy |
| Q50926633 | MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. |
| Q38690430 | Modeling tumor progression via the comparison of stage-specific graphs. |
| Q97419128 | NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner |
| Q93252546 | New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer |
| Q33869781 | New insights into the role of EMT in tumor immune escape. |
| Q58791982 | Next Generation Cancer Vaccines-Make It Personal! |
| Q47162554 | Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling. |
| Q91871623 | PA28α/β Promote Breast Cancer Cell Invasion and Metastasis via Down-Regulation of CDK15 |
| Q39390852 | Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems Theory |
| Q90225046 | Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC |
| Q50077966 | Proteasome dysregulation in human cancer: implications for clinical therapies |
| Q92923068 | Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer |
| Q89860448 | Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis |
| Q64890767 | Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response. |
| Q45822425 | Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). |
| Q57296955 | Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity |
| Q52317592 | STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. |
| Q55008935 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. |
| Q47673602 | Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric |
| Q90587477 | Testing the gene expression classification of the EMT spectrum |
| Q92083224 | The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System |
| Q47100314 | The combination of checkpoint immunotherapy and targeted therapy in cancer |
| Q47165961 | Transcription factor SPZ1 may promote TWIST-mediated epithelial-mesenchymal transition in thoracic malignancies |
| Q48692756 | Trends in immunotherapy for brain metastases |
Search more.